title: Higher hemoglobin levels and quality of life in patients with advanced chronic kidney disease: no longer a moving target?
abstract: International clinical practice guidelines for the management of anemia in chronic kidney disease suggest target hemoglobin levels ≤ 11.5 g/dl (115 g/l), with individualized consideration of slightly higher hemoglobin targets to improve quality of life. An updated meta-analysis of randomized trials demonstrates no significant improvement in quality of life with erythropoietin-stimulating agent therapy targeting higher hemoglobin levels. Limitations of the available data suggest that individualized targets should nonetheless remain an option in future clinical practice guidelines.
authors.affiliation: Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: christina.wyatt@mssm.edu.
authors.forename: Christina M
authors.initials: CM
authors.lastname: Wyatt
authors.affiliation: Inserm U-1018, Team 5, Hôpital Paul Brousse, Paris-Sud University and Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Villejuif, France.
authors.forename: Tilman B
authors.initials: TB
authors.lastname: Drueke
mesh_terms: D000740:Anemia / Q000188:drug therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins; D006801:Humans; D011788:Quality of Life; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin